<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="no">
	<id>https://transwiki.no/w/index.php?action=history&amp;feed=atom&amp;title=Ofte_stilte_sp%C3%B8rsm%C3%A5l</id>
	<title>Ofte stilte spørsmål - Sideversjonshistorikk</title>
	<link rel="self" type="application/atom+xml" href="https://transwiki.no/w/index.php?action=history&amp;feed=atom&amp;title=Ofte_stilte_sp%C3%B8rsm%C3%A5l"/>
	<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;action=history"/>
	<updated>2026-11-19T17:52:24Z</updated>
	<subtitle>Versjonshistorikk for denne siden på wikien</subtitle>
	<generator>MediaWiki 1.47.0-alpha</generator>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=283&amp;oldid=prev</id>
		<title>Icarus: kategori</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=283&amp;oldid=prev"/>
		<updated>2026-10-20T08:10:12Z</updated>

		<summary type="html">&lt;p&gt;kategori&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 20. okt. 2026 kl. 09:10&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l25&quot;&gt;Linje 25:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 25:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|description=Ofte stilte spørsmål om transbehandling i Norge&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|description=Ofte stilte spørsmål om transbehandling i Norge&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Norsk]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-240:rev-283:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Icarus</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=240&amp;oldid=prev</id>
		<title>Icarus på 7. okt. 2026 kl. 11:53</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=240&amp;oldid=prev"/>
		<updated>2026-10-07T11:53:13Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 7. okt. 2026 kl. 12:53&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l23&quot;&gt;Linje 23:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 23:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|title=Ofte stilte spørsmål&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|title=Ofte stilte spørsmål&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|title_mode=prepend&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|title_mode=prepend&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|keywords=hrt,transgender,wiki,faq&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-added&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|description=Ofte stilte spørsmål om transbehandling i Norge&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;|description=Ofte stilte spørsmål om transbehandling i Norge&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-231:rev-240:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Icarus</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=231&amp;oldid=prev</id>
		<title>Icarus på 7. okt. 2026 kl. 11:47</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=231&amp;oldid=prev"/>
		<updated>2026-10-07T11:47:31Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 7. okt. 2026 kl. 12:47&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l19&quot;&gt;Linje 19:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 19:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;{{#seo:&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|title=Ofte stilte spørsmål&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|title_mode=prepend&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|keywords=hrt,transgender,wiki,faq&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;|description=Ofte stilte spørsmål om transbehandling i Norge&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;}}&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-192:rev-231:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Icarus</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=192&amp;oldid=prev</id>
		<title>Cyber på 2. okt. 2026 kl. 22:32</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=192&amp;oldid=prev"/>
		<updated>2026-10-02T22:32:35Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 2. okt. 2026 kl. 23:32&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l11&quot;&gt;Linje 11:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 11:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326dced5063c4b7465cf6b/1731358158768/HKS+rutiner+-+mask.+hormonbehandling.pdf HKS sine rutiner] rapporterer T 14-28 nmol/L (404-808 ng/dL).&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326dced5063c4b7465cf6b/1731358158768/HKS+rutiner+-+mask.+hormonbehandling.pdf HKS sine rutiner] rapporterer T 14-28 nmol/L (404-808 ng/dL).&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på [https://metodebok.no/emne/W7X5vPgW mannlige referanseverdier for testosteron], som for menn &amp;lt;50 år vil være T 8,32–30,20 nmol/L (240-871 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på [https://metodebok.no/emne/W7X5vPgW mannlige referanseverdier for testosteron], som for menn &amp;lt;50 år vil være T 8,32–30,20 nmol/L (240-871 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;== Hvordan endrer jeg juridisk kjønn? ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Se egen side [[Juridisk kjønnsendring|juridisk kjønnsendring]].&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Kan jeg (en transfeminin person) få injeksjoner? ==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Kan jeg (en transfeminin person) få injeksjoner? ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-167:rev-192:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Cyber</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=167&amp;oldid=prev</id>
		<title>Cyber: Cyber flyttet siden Ofte Stilte Spørsmål til Ofte stilte spørsmål: Feilstavet tittel</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=167&amp;oldid=prev"/>
		<updated>2026-10-02T12:26:29Z</updated>

		<summary type="html">&lt;p&gt;Cyber flyttet siden &lt;a href=&quot;/w/index.php?title=Ofte_Stilte_Sp%C3%B8rsm%C3%A5l&amp;amp;action=edit&amp;amp;redlink=1&quot; class=&quot;new&quot; title=&quot;Ofte Stilte Spørsmål (siden finnes ikke)&quot;&gt;Ofte Stilte Spørsmål&lt;/a&gt; til &lt;a href=&quot;/wiki/Ofte_stilte_sp%C3%B8rsm%C3%A5l&quot; title=&quot;Ofte stilte spørsmål&quot;&gt;Ofte stilte spørsmål&lt;/a&gt;: Feilstavet tittel&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 2. okt. 2026 kl. 13:26&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;4&quot; class=&quot;diff-notice&quot; lang=&quot;nb&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(Ingen forskjell)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;!-- diff cache key my_wiki:diff:1.41:old-166:rev-167 --&gt;
&lt;/table&gt;</summary>
		<author><name>Cyber</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=166&amp;oldid=prev</id>
		<title>Cyber på 2. okt. 2026 kl. 12:26</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=166&amp;oldid=prev"/>
		<updated>2026-10-02T12:26:00Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 2. okt. 2026 kl. 13:26&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Linje 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{Language bar|en=Frequently asked questions}}&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;{{Language bar|en=Frequently asked questions}}&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;= Ofte &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Stilte Spørsmål &lt;/del&gt;=&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;= Ofte &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;stilte spørsmål &lt;/ins&gt;=&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;===&lt;/del&gt;== Hva bør nivåene på blodprøvene mine ligge på? &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;===&lt;/del&gt;==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Hva bør nivåene på blodprøvene mine ligge på? ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transfeminine personer siktes &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;østradiol &lt;/del&gt;på &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;367&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;734 pmol&lt;/del&gt;/L (100-200 pg/mL) og &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testosteron &lt;/del&gt;på &amp;lt;1&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.735 &lt;/del&gt;nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;www&lt;/del&gt;.&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;tandfonline.com&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;doi&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;pdf&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;10.1080&lt;/del&gt;/&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;26895269&lt;/del&gt;.&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;2022.2100644 &lt;/del&gt;SOC8]. De nøyaktige tallene kan variere fra behandler til behandler&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326da73b559b29ef3104f6/1731358119507/HKS+rutiner+-+fem.+hormonbehandling.pdf HKS sine rutiner] rapporterer &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;for eksempel 200&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;1100 pmol&lt;/del&gt;/L og &amp;lt;2 nmol/L (&amp;lt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;57.7 &lt;/del&gt;ng/dL). [https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;350&lt;/del&gt;-&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;700 &lt;/del&gt;nmol/L (95-191 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transfeminine personer siktes &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;S-Østradiol &lt;/ins&gt;på &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;0,37&lt;/ins&gt;-&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;0,73 nmol&lt;/ins&gt;/L (100-200 pg/mL) og &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;S-Testosteron &lt;/ins&gt;på &amp;lt;1&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;,7 &lt;/ins&gt;nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;wpath&lt;/ins&gt;.&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;org/wp-content&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;uploads&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;2024&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;11&lt;/ins&gt;/&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;SOC8-Norwegian-May-16-2023_clean&lt;/ins&gt;.&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;pdf &lt;/ins&gt;SOC8]. De nøyaktige tallene kan variere fra behandler til behandler&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326da73b559b29ef3104f6/1731358119507/HKS+rutiner+-+fem.+hormonbehandling.pdf HKS sine rutiner] rapporterer &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Ø 0,2&lt;/ins&gt;-&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;1,1 nmol&lt;/ins&gt;/L og &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;T &lt;/ins&gt;&amp;lt;2 nmol/L (&amp;lt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;58 &lt;/ins&gt;ng/dL).&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;Ø 0,35&lt;/ins&gt;-&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;0,70 &lt;/ins&gt;nmol/L (95-191 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transmaskuline personer siktes &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;testosteron &lt;/del&gt;på 13&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.88&lt;/del&gt;-24&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.29 &lt;/del&gt;nmol/L (400-700 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326dced5063c4b7465cf6b/1731358158768/HKS+rutiner+-+mask.+hormonbehandling.pdf HKS sine rutiner] rapporterer &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;for eksempel &lt;/del&gt;14-28 nmol/L (404-808 ng/dL). [https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på [https://metodebok.no/emne/W7X5vPgW mannlige referanseverdier for testosteron], som for menn &amp;lt;50 år vil være 8,32–30,20 nmol/L (240-871 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transmaskuline personer siktes &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;S-Testosteron &lt;/ins&gt;på 13&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;,9&lt;/ins&gt;-24&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;,3 &lt;/ins&gt;nmol/L (400-700 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;.&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326dced5063c4b7465cf6b/1731358158768/HKS+rutiner+-+mask.+hormonbehandling.pdf HKS sine rutiner] rapporterer &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;T &lt;/ins&gt;14-28 nmol/L (404-808 ng/dL).&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på [https://metodebok.no/emne/W7X5vPgW mannlige referanseverdier for testosteron], som for menn &amp;lt;50 år vil være &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;T &lt;/ins&gt;8,32–30,20 nmol/L (240-871 pg/mL).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;===&lt;/del&gt;== Kan jeg (en transfeminin person) få injeksjoner? &lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;===&lt;/del&gt;==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== Kan jeg (en transfeminin person) få injeksjoner? ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;I Norge er det ingen injeksjonspreparater som har markedsføringstillatelse. Dette kommer hovedsakelig av at Norge er et lite marked for denne typen preparat og dermed er lite gunsig for selgere på markedsføre i.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;I Norge er det ingen injeksjonspreparater som har markedsføringstillatelse. Dette kommer hovedsakelig av at Norge er et lite marked for denne typen preparat og dermed er lite gunsig for selgere på markedsføre i.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-165:rev-166:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Cyber</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=165&amp;oldid=prev</id>
		<title>Fremmedart: add language bar</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=165&amp;oldid=prev"/>
		<updated>2026-10-02T12:14:10Z</updated>

		<summary type="html">&lt;p&gt;add language bar&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 2. okt. 2026 kl. 13:14&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Linje 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;{{Language bar|en=Frequently asked questions}}&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;= Ofte Stilte Spørsmål =&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;= Ofte Stilte Spørsmål =&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-163:rev-165:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Fremmedart</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=163&amp;oldid=prev</id>
		<title>Cyber på 2. okt. 2026 kl. 11:55</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=163&amp;oldid=prev"/>
		<updated>2026-10-02T11:55:58Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;nb&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Eldre sideversjon&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Sideversjonen fra 2. okt. 2026 kl. 12:55&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l2&quot;&gt;Linje 2:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linje 2:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===== Hva bør nivåene på blodprøvene mine ligge på? =====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===== Hva bør nivåene på blodprøvene mine ligge på? =====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transfeminine personer siktes østradiol på 367-734 pmol/L (100-200 pg/mL) og testosteron på &amp;lt;1.735 nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 200-1100 pmol/L og &amp;lt;2 nmol/L (&amp;lt;57.7 ng/dL).  &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transfeminine personer siktes østradiol på 367-734 pmol/L (100-200 pg/mL) og testosteron på &amp;lt;1.735 nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326da73b559b29ef3104f6/1731358119507/HKS+rutiner+-+fem.+hormonbehandling.pdf &lt;/ins&gt;HKS sine rutiner&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;] &lt;/ins&gt;rapporterer for eksempel 200-1100 pmol/L og &amp;lt;2 nmol/L (&amp;lt;57.7 ng/dL&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;). [https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på 350-700 nmol/L (95-191 pg/mL&lt;/ins&gt;).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transmaskuline personer siktes testosteron på 13.88-24.29 nmol/L (400-700 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 14-28 nmol/L (404-808 ng/dL).&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;For transmaskuline personer siktes testosteron på 13.88-24.29 nmol/L (400-700 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[https://static1.squarespace.com/static/63a1caefce33c705009a0c2a/t/67326dced5063c4b7465cf6b/1731358158768/HKS+rutiner+-+mask.+hormonbehandling.pdf &lt;/ins&gt;HKS sine rutiner&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;] &lt;/ins&gt;rapporterer for eksempel 14-28 nmol/L (404-808 ng/dL&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;). [https://metodebok.no/emne/MSNJB292/kj%C3%B8nnsinkongruens-endokrinologisk-behandling Metodebok] sikter på [https://metodebok.no/emne/W7X5vPgW mannlige referanseverdier for testosteron], som for menn &amp;lt;50 år vil være 8,32–30,20 nmol/L (240-871 pg/mL&lt;/ins&gt;).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===== Kan jeg (en transfeminin person) få injeksjoner? =====&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;===== Kan jeg (en transfeminin person) få injeksjoner? =====&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;I Norge er det ingen injeksjonspreparater som har markedsføringstillatelse. Dette kommer hovedsakelig av at Norge er et lite marked for denne typen preparat og dermed er lite gunsig for selgere på markedsføre i.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;I Norge er det ingen injeksjonspreparater som har markedsføringstillatelse. Dette kommer hovedsakelig av at Norge er et lite marked for denne typen preparat og dermed er lite gunsig for selgere på markedsføre i.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key my_wiki:diff:1.41:old-162:rev-163:php=table --&gt;
&lt;/table&gt;</summary>
		<author><name>Cyber</name></author>
	</entry>
	<entry>
		<id>https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=162&amp;oldid=prev</id>
		<title>Cyber: Ny side: = Ofte Stilte Spørsmål =  ===== Hva bør nivåene på blodprøvene mine ligge på? ===== For transfeminine personer siktes østradiol på 367-734 pmol/L (100-200 pg/mL) og testosteron på &lt;1.735 nmol/L (&lt;50 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 200-1100 pmol/L og &lt;2 nmol/L (&lt;57.7 ng/dL).   For transmaskuline personer sik…</title>
		<link rel="alternate" type="text/html" href="https://transwiki.no/w/index.php?title=Ofte_stilte_sp%C3%B8rsm%C3%A5l&amp;diff=162&amp;oldid=prev"/>
		<updated>2026-10-02T11:42:31Z</updated>

		<summary type="html">&lt;p&gt;Ny side: = Ofte Stilte Spørsmål =  ===== Hva bør nivåene på blodprøvene mine ligge på? ===== For transfeminine personer siktes østradiol på 367-734 pmol/L (100-200 pg/mL) og testosteron på &amp;lt;1.735 nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 200-1100 pmol/L og &amp;lt;2 nmol/L (&amp;lt;57.7 ng/dL).   For transmaskuline personer sik…&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Ny side&lt;/b&gt;&lt;/p&gt;&lt;div&gt;= Ofte Stilte Spørsmål =&lt;br /&gt;
&lt;br /&gt;
===== Hva bør nivåene på blodprøvene mine ligge på? =====&lt;br /&gt;
For transfeminine personer siktes østradiol på 367-734 pmol/L (100-200 pg/mL) og testosteron på &amp;lt;1.735 nmol/L (&amp;lt;50 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 200-1100 pmol/L og &amp;lt;2 nmol/L (&amp;lt;57.7 ng/dL). &lt;br /&gt;
&lt;br /&gt;
For transmaskuline personer siktes testosteron på 13.88-24.29 nmol/L (400-700 ng/dL) ifølge WPATH [https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 SOC8]. De nøyaktige tallene kan variere fra behandler til behandler, HKS sine rutiner rapporterer for eksempel 14-28 nmol/L (404-808 ng/dL).&lt;br /&gt;
&lt;br /&gt;
===== Kan jeg (en transfeminin person) få injeksjoner? =====&lt;br /&gt;
I Norge er det ingen injeksjonspreparater som har markedsføringstillatelse. Dette kommer hovedsakelig av at Norge er et lite marked for denne typen preparat og dermed er lite gunsig for selgere på markedsføre i.&lt;br /&gt;
Dette betyr at man ikke kan få injeksjoner på resept i Norge med mindre man har [https://www.dmp.no/godkjenningsfritak godkjenningsfritak] fra Direktoratet for medisinske produkter (DMP). Dette søkes om av din medisinske behandler, gis for opp til ett år av gangen, og må fornøyes jevnlig. Her er det som regel krav om at ingen andre østradiolpreparater har effekt for den søknaden gjelder.&lt;/div&gt;</summary>
		<author><name>Cyber</name></author>
	</entry>
</feed>